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reconditioning is the process by which brief, repetitive
pisodes of ischemia reduce the size of a subsequent
yocardial infarction. Since the discovery of ischemic pre-
onditioning by Murry et al. (1) almost two decades ago,
housands of studies have pursued its mechanism(s) and
ought therapeutic realization of this unique adaptive re-
ponse to a physiologic stress. Although mechanistic under-
tanding has progressed, translation into clinical utility has
een elusive. Indeed, the pursuit of this goal has been akin
o a modern version of Jason’s quest for the Golden Fleece.
See page 1511
Current understanding of preconditioning and unre-
olved issues have been reviewed recently (2,3). Early studies
emonstrated that ischemic preconditioning was unique in
omparison with myriad other approaches to limit infarct
ize. Under controlled conditions in laboratory animals, its
ffects are singularly profound and consistent. Infarct size is
educed by as much as 70%, arrhythmias decreased, and
T-segment elevation attenuated (1,4). These findings have
een reproducible in all mammalian species studied and are
ot dependent on coronary collaterals. However, cardiopro-
ection is not observed in the absence of coronary reperfu-
ion and the interval, during which protection can occur
fter induction of the preconditioning stimulus is limited. In
he canine heart, for example, there is no reduction in the
ize of infarction occurring 3 h after induction of precon-
itioning (1). However, if the delay from preconditioning
nset is increased to 24 h, the protective effect is restored.
hus, preconditioning comprises two phases referred to as
arly, or “classical,” and delayed, or “second window.”
Although not fully clarified, the mechanisms underlying
schemic preconditioning have been unveiled to a considerable
xtent (2–4). Classical preconditioning appears to involve a
omplex series of reactions initiated by agonists such as
denosine, formed during ischemia, that activate second mes-
enger pathways involving protein or tyrosine kinases with
ubsequent opening of mitochondrial adenosine triphosphate
ATP)-sensitive potassium channels (KATP) and reduction in
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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lthough responding to similar agonists, likely involves activa-
ion of nuclear factor-kappa-B and transcription of several
ediators, such as Bcl-2, that maintain the mitochondrial
ransition pore in its closed conformation (6).
There is evidence for ischemic preconditioning in hu-
ans in both acute and chronic coronary heart disease.
linical settings include exercise, coronary artery angio-
lasty, coronary bypass graft surgery, and acute myocardial
nfarction (AMI). It is well documented that a second bout
f exercise is associated with delayed onset of angina and
ess ST-segment deviation than occurs with the initial
xertion, a finding known as the “warm-up” phenomenon
7,8). Similar results have been observed after sequential
ardiac pacing stress (9). These studies suggest that precon-
itioning can be induced by demand ischemia as well as
nterruption of coronary blood flow. The latter paradigm
pplies to coronary angioplasty during which repeated
alloon inflations produce a decrease in electrocardiographic
nd biochemical evidence of ischemia, adaptations that can
e simulated or blocked by agonists and antagonists of the
denosine-KATP channel pathway (10–12). Although re-
ults during cardiac surgery have varied, brief periods of
ortic cross clamping to induce preconditioning before
rolonged cross clamping have yielded biochemical evidence
f myocardial protection in some studies (13).
The foregoing experimental and clinical studies provide a
ackground for reports of improved outcome in AMI
atients who experience angina preceding the infarction.
ompared with those without antecedent angina, patients
ith angina have had decreases in mortality, pump failure,
rrhythmias, and peak cardiac serum enzyme levels as well
s enhanced recovery of cardiac contractile function (14–
7). In these studies, preinfarct angina has occurred within
4 to 72 h of AMI, consistent with the temporal relations of
arly and delayed preconditioning.
In this issue of the Journal, Solomon et al. (18) extend our
nderstanding of the complex interrelation between pre-infarct
ngina, AMI outcome, and the possible role of precondition-
ng in their investigation of postinfarction left ventricular (LV)
emodeling. They studied a subgroup of the Healing and Early
fterload Reducing Therapy (HEART) trial of immediate
ersus delayed treatment with ramipril in patients with anterior
-wave infarction. In accord with previous evidence of smaller
nfarctions associated with preinfarct angina (13), Solomon et
l. (18) detected lower peak creatine kinase levels and reduced
nfarct segment length in their patients with angina preceding
MI. However, theirs is the first report of attenuation of LV
emodeling in patients with preinfarct angina, with mainte-
ance of this finding at 90 days after AMI. These results
xtend previous data showing acute benefits on LV function
19). They also observed that patients with rest angina had less
V remodeling than those with either stable angina or no
ngina preceding AMI. Furthermore, although previous stud-
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Editorial Comment May 5, 2004:1515–6y one to three days (19,20), Solomon et al. (18) report protective
ffects with angina occurring up to three months before AMI. In
ddition, as has been previously reported, angina did not confer a
rotective effect in their diabetic patients (21).
The findings of Solomon et al. (18) are provocative. Their
ata suggest a widening of the window within which angina-
elated cardioprotection can be initiated before AMI and
aintained thereafter. Cardioprotective effects associated with
reinfarct angina implicate preconditioning as a potential
echanism. The three-month interval by which angina could
recede AMI in this study is most interesting because it greatly
xceeds the recognized period within which preconditioning is
nitiated. However, although not specified in the results, it is
ossible that many of these patients also had angina proximate
o their AMI. Additionally, it is also likely that in the patients
ith rest angina, in whom cardioprotection was greatest, this
ymptom had a close temporal relation to AMI.
Protective mechanisms other than preconditioning war-
ant consideration in this study, including augmented cor-
nary collateral vessels, the development of which is favored
y the prolonged interval between angina and subsequent
MI. In this regard, it is noted that the angina patients had
lmost twice the frequency of previous MI than those
ithout angina (21% vs. 11%), consistent with increased
oronary collaterals in the former (22). The time to throm-
olysis in this study was similar in the angina and nonangina
atients. However, there is experimental evidence that
reinfarct ischemia can facilitate thrombolysis by the
latelet-inhibiting actions of adenosine (23), thereby favor-
ng improved clinical outcome. This potential mechanism
ould apply to patients with angina proximate to AMI.
lthough medications did not differ in the angina and
onangina patients at 90 days, it is noteworthy that both
spirin and beta-blocker use on admission were significantly
igher in those with angina. These differences could also
nfluence infarct size and subsequent LV remodeling. Fi-
ally, it is not known how the various dosing regimens of
amipril related to LV remodeling.
Other than early reperfusion, ischemic preconditioning is
he most potent means of limiting infarct size, an essential
arget in the challenge to reduce mortality from coronary
eart disease. The report of Solomon et al. (18) reflects the
omplexities of considering preconditioning in the clinical
etting. However, their provocative findings complement
urrent efforts to better understand this cardioprotective
echanism and contribute to pursuit of this potential
herapeutic Golden Fleece.
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ivision of Cardiovascular Medicine, Suite 2520, 4860 Y Street,
acramento, California 95817. E-mail: eaamsterdam@ucdavis.edu.
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